First quarterly filings as a public company following the April 2026 reverse takeover with OpenSesame Acquisition Corp. Peptide manufacturing revenue expected in August 2026, with production capacity ...
Vector Science & Therapeutics and Caresyntax Announce Real-World Evidence Partnership for VectorMist
Caresyntax will design and operate a multi-phase real-world evidence program for Vector, culminating in a prospective comparative registry across a network of partner surgical facilities. The program ...
Vancouver, British Columbia--(Newsfile Corp. - April 24, 2026) - Vector Science and Therapeutics Corp. (TSXV: PAIN) (formerly OpenSesame Acquisition Corp.) ("Vector" or the "Company") is pleased to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results